AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.910-14.110 for the period, compared to the consensus estimate of 14.250. The company issued revenue guidance of -. AbbVie also updated its Q2 2026 guidance to 3.570-3.610 EPS.

Analyst Ratings Changes

Several research analysts have weighed in on ABBV shares. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Guggenheim restated a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research note on Thursday, April 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

AbbVie Trading Down 0.0%

NYSE ABBV opened at $254.71 on Wednesday. The stock has a market cap of $450.02 billion, a PE ratio of 125.47, a PEG ratio of 0.84 and a beta of 0.30. AbbVie has a 12 month low of $184.63 and a 12 month high of $261.64. The company’s 50-day moving average price is $222.39 and its 200-day moving average price is $220.69.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the previous year, the company earned $2.46 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts forecast that AbbVie will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved AbbVie’s TEPKINLY combination for relapsed or refractory follicular lymphoma, expanding the company’s oncology franchise and potentially adding a new growth driver. Article Title
• Positive Sentiment: Phase 3 data showed strong efficacy for TEPKINLY + R2, including statistically significant progression-free survival and response rate improvements, which supports the commercial outlook for the drug. Article Title
• Neutral Sentiment: AbbVie also received analyst attention and favorable dividend-stock mentions, but these items are more sentiment-driven and do not materially change the near-term fundamental story. Article Title
• Negative Sentiment: AbbVie’s updated 2026 and second-quarter EPS guidance came in below consensus, which could weigh on investor sentiment despite the positive pipeline news. Guidance update

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC increased its stake in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter valued at approximately $31,000. Quarry LP purchased a new position in shares of AbbVie in the third quarter worth $41,000. Finally, Jessup Wealth Management Inc acquired a new stake in shares of AbbVie during the fourth quarter worth $42,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.